Core Insights - The integration of AI into the design process is a significant trend, emphasizing the need for designers to adopt system thinking and prompt design skills to enhance their work and adapt to the evolving landscape of design [1][4]. Group 1: System Thinking in Design - Establishing a design system requires a holistic perspective, considering the overall product vision rather than just creating a component library. This approach ensures that designs are adaptable and aligned with long-term product goals, avoiding fragmentation [3]. Group 2: Importance of Prompt Design - The rapid advancement of AI necessitates that designers learn prompt design skills, as AI can assist throughout the entire design process. Embracing AI capabilities can significantly enhance design efficiency and quality [4]. Group 3: Principles of High-Quality UI Prompt Design - High-quality UI prompts should adhere to three core principles: clear semantics to convey design intent, a structured framework to guide AI outputs, and explicit goals to avoid ambiguity in instructions [6]. Group 4: AI's Role in the Design Process - AI's capabilities extend beyond zero-code prototype generation; it can assist in conceptualizing product logic and provide diverse insights during discussions, acting as a comprehensive collaborative partner throughout the design workflow [7]. Group 5: Shifting Value of Designers - As AI automates interface creation, the role of designers will shift from creators to evaluators and thinkers. Designers will need to focus on judgment, aesthetics, and the rationale behind design decisions, ensuring effective collaboration with AI [8]. Group 6: Future of AI Browsers - Future AI browsers are expected to evolve from simple web access tools to intelligent assistants that understand user preferences and provide personalized content and task support, enhancing user experience beyond traditional browsing [10]. Group 7: Industry Engagement - The enthusiasm for AI and human-machine collaboration at industry events highlights the potential for innovative applications and design synergies, positioning platforms like IXDC as valuable resources for inspiration and industry vitality [11].

Core Viewpoint - Liu Ruopeng, Chairman of Guangqi Technology, disclosed the full-chain practice path of metamaterial technology from laboratory breakthroughs to industrialization at the "2025 Entrepreneur Boao Forum" [1] Group 1: Metamaterials - Metamaterials are referred to as the "gene editing technology" in the materials field, highlighting their importance in overcoming the limitations of natural material properties to achieve extraordinary performance through artificial customization [1] - The research has shifted from "material selection" to "functional customization," representing a successful practice of the "reverse design" paradigm [1] Group 2: Future Trends - Liu Ruopeng indicated that a large number of emerging technology companies driven by AI design will emerge, bringing not only disruptive technologies but also a complete restructuring of the existing industrial chain and division of labor [1]

Core Viewpoint - The in vivo CAR-T field has rapidly evolved over three years, marked by significant acquisitions and clinical advancements, culminating in major deals such as AbbVie’s $2.1 billion acquisition of Capstan Therapeutics and BMS’s $1.5 billion acquisition of Orbital Therapeutics [3][4]. Group 1: Acquisitions and Market Activity - AbbVie announced the acquisition of Capstan Therapeutics for $2.1 billion in cash, highlighting the growing interest in in vivo CAR-T therapies [3]. - BMS acquired Orbital Therapeutics for $1.5 billion, expanding its portfolio into the in vivo CAR-T cell therapy space [4]. - These acquisitions reflect a broader trend of increasing investment and collaboration in the CAR-T sector, indicating a robust market outlook [3][4]. Group 2: Technological Advancements - BMS's acquisition of Orbital enhances its cell therapy research platform, focusing on a potential best-in-class therapy aimed at autoimmune diseases [6]. - The therapy OTX-201, developed by Orbital, is in the pre-IND research stage and is expected to enter clinical trials in the first half of 2026 [6]. - OTX-201 utilizes optimized circular RNA (circRNA) to generate CAR-T cells in vivo, targeting CD19 to treat B-cell driven autoimmune diseases [7]. Group 3: Research and Development Focus - Orbital Therapeutics aims to develop next-generation RNA drugs that reprogram cells to treat diseases at their source, offering a simpler and safer alternative to current CAR-T therapies [10]. - The company’s platform integrates circRNA, linear RNA, targeted delivery systems, and AI-driven design to create durable and programmable therapies [10]. - In addition to autoimmune diseases, Orbital is also exploring in vivo CAR-T therapies for cancer and developing next-generation mRNA vaccines [12].